Your browser doesn't support javascript.
loading
A model-based approach leveraging in vitro data to support dose selection from the outset: A framework for bispecific antibodies in immuno-oncology.
Sánchez, Javier; Claus, Christina; Albrecht, Rosmarie; Gaillard, Brenda C; Marinho, Joana; McIntyre, Christine; Tanos, Tamara; Boehnke, Axel; Friberg, Lena E; Jönsson, Siv; Frances, Nicolas.
Afiliación
  • Sánchez J; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.
  • Claus C; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
  • Albrecht R; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Zurich, Schlieren, Switzerland.
  • Gaillard BC; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Zurich, Schlieren, Switzerland.
  • Marinho J; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Zurich, Schlieren, Switzerland.
  • McIntyre C; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Zurich, Schlieren, Switzerland.
  • Tanos T; Roche Pharma Research and Early Development, Roche Innovation Center Welwyn, Welwyn Garden City, UK.
  • Boehnke A; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.
  • Friberg LE; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.
  • Jönsson S; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
  • Frances N; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
CPT Pharmacometrics Syst Pharmacol ; 12(11): 1804-1818, 2023 Nov.
Article en En | MEDLINE | ID: mdl-37964753
FAP-4-1BBL is a bispecific antibody exerting 4-1BB-associated T-cell activation only while simultaneously bound to the fibroblast activation protein (FAP) receptor, expressed on the surface of cancer-associated fibroblasts. The trimeric complex formed when FAP-4-1BBL is simultaneously bound to FAP and 4-1BB represents a promising mechanism to achieve tumor-specific 4-1BB stimulation. We integrated in vitro data with mathematical modeling to characterize the pharmacology of FAP-4-1BBL as a function of trimeric complex formation when combined with the T-cell engager cibisatamab. This relationship was used to prospectively predict a range of clinical doses where trimeric complex formation is expected to be at its maximum. Depending on the dosing schedule and FAP-4-1BBL plasma: tumor distribution, doses between 2 and 145 mg could lead to maximum trimeric complex formation in the clinic. Due to the expected variability in both pharmacokinetic and FAP expression in the patient population, we predict that detecting a clear dose-response relationship would remain difficult without a large number of patients per dose level, highlighting that mathematical modeling techniques based on in vitro data could aid dose selection.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Biespecíficos / Neoplasias Límite: Humans Idioma: En Revista: CPT Pharmacometrics Syst Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Biespecíficos / Neoplasias Límite: Humans Idioma: En Revista: CPT Pharmacometrics Syst Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Estados Unidos